SOX2 and cancer: Elevated SOX2-OT expression was significantly related to shorter OS (HR = 2.026, 95% CI: 1.691-2.428, <i>P</i> < 0.0001) and disease-free survival (DFS) (HR = 2.554, 95% CI: 1.261-5.174, <i>P</i> = 0.0092) in cancer patients.